close 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Investeringen brengen risico`s met zich mee en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 74% van de retail beleggers lijdt verlies op de handel in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

9.33 1.08

Strong Buy

Prijsupdate 27 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.95

Max

9.48

Belangrijke statistieken

By Trading Economics

Inkomsten

-69M

-102M

Verkoop

-10M

34M

EPS

-2.227

Winstmarge

-299.886

Werknemers

228

EBITDA

4.7M

-18M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+78.29% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

27M

184M

Vorige openingsprijs

8.25

Vorige sluitingsprijs

9.33

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 feb 2026, 23:53 UTC

Populaire aandelen

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

DJ

Lezen

27 feb 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

DJ

Lezen

27 feb 2026, 17:55 UTC

Populaire aandelen

Toronto Stocks Decline, But Remain On Track for Weekly Gains

DJ

Lezen

27 feb 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

DJ

Lezen

27 feb 2026, 23:33 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

DJ

Lezen

27 feb 2026, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

DJ

Lezen

27 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

27 feb 2026, 21:30 UTC

Winsten

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

DJ

Lezen

27 feb 2026, 21:30 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

DJ

Lezen

27 feb 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

DJ

Lezen

27 feb 2026, 21:17 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

DJ

Lezen

27 feb 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

DJ

Lezen

27 feb 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

DJ

Lezen

27 feb 2026, 21:00 UTC

Winsten

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

DJ

Lezen

27 feb 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

DJ

Lezen

27 feb 2026, 20:24 UTC

Marktinformatie

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

DJ

Lezen

27 feb 2026, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

DJ

Lezen

27 feb 2026, 20:12 UTC

Marktinformatie

Nike Seen With Further Challenges in China -- Market Talk

DJ

Lezen

27 feb 2026, 19:44 UTC

Marktinformatie

Gold Caps Historic Month -- Market Talk

DJ

Lezen

27 feb 2026, 19:39 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

DJ

Lezen

27 feb 2026, 19:38 UTC

Winsten

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

DJ

Lezen

27 feb 2026, 18:53 UTC

Acquisities, Fusies, Overnames

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

DJ

Lezen

27 feb 2026, 18:45 UTC

Winsten

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

DJ

Lezen

27 feb 2026, 18:45 UTC

Marktinformatie

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

DJ

Lezen

27 feb 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

27 feb 2026, 17:07 UTC

Winsten

Pemex Cuts 4Q Loss As Operating Results Improve

DJ

Lezen

27 feb 2026, 17:00 UTC

Marktinformatie

Corn Rides Oil Momentum Higher -- Market Talk

DJ

Lezen

27 feb 2026, 16:31 UTC

Marktinformatie

Canadian Economy Shows Resilience -- Market Talk

DJ

Lezen

27 feb 2026, 16:17 UTC

Marktinformatie

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

DJ

Lezen

27 feb 2026, 15:49 UTC

Winsten

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

78.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.67 USD  78.29%

Hoogste 23 USD

Laagste 12 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

1,050.93

↑ +2.96%

JNJ

Johnson and Johnson

248.43

↑ +2.06%

ABBV

AbbVie Inc

231.99

↑ +3.33%

NVS

Novartis AG

168.32

↑ +1.89%

MRK

Merck & Co Inc.

123.72

↑ +3.77%
help-icon Live chat